|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | A61K 31/445 | |
| A61K 31/40 | |||
| A61K 31/485 | |||
| A61K 31/135 | |||
| A61P 3/04 |
| (11) | Patento numeris | 1505974 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 03752716.5 |
| Europos patento paraiškos padavimo data | 2003-04-28 | |
| (97) | Europos patento paraiškos paskelbimo data | 2005-02-16 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2009-04-22 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2003/004428 |
| Data | 2003-04-28 |
| (87) | Numeris | WO 2003/097051 |
| Data | 2003-11-27 |
| (30) | Numeris | Data | Šalis |
| 02011047 | 2002-05-17 | EP |
| (72) |
WEBER, Frank, DE
JACOB, Jutta, DE
BARBER, Andrew, DE
GOTTSCHLICH, Rudolf, DE
|
| (73) |
Tioga Pharmaceuticals, Inc.,
c/o Forward Ventures 9393 Towne Centre Dr. Suite 200, San Diego, CA 92121,
US
|
| (54) | USE OF COMPOUNDS THAT ARE EFFECTIVE AS SELECTIVE OPIATE RECEPTOR MODULATORS |
| USE OF COMPOUNDS THAT ARE EFFECTIVE AS SELECTIVE OPIATE RECEPTOR MODULATORS |